The use of umbilical or placental donor cord blood transplantation (CBT) in children with malignant and non-malignant diseases has witnessed important progress, mainly because of better cord blood donor choice and patient selection translating into better patient outcome. Approximately 2000 children with malignant diseases (about 75 % with acute leukemias) have been transplanted with a related (n ¼ 199) or unrelated CBT (UCBT, n ¼ 1663) and reported to Eurocord registry from 1990-2008. Disease-specific studies have been carried out after UCBT for acute lymphoblastic and myeloid leukemia and myelodysplastic syndromes in others to identify the risk factors that may improve outcomes. Outcomes after CBT have been compared with other alternative allogeneic hematopoietic SCT (HSCT) donors. Briefly, after CBT, myeloid engraftment is delayed, acute and chronic GVHD decreased and disease-free survival was not statistically different when compared with HLA identical and other alternative HSCT donor. Therefore, any physician has to carefully evaluate, for each single pediatric patient in need of an allograft, all the possible alternatives in order to choose the best hematopoietic stem cell donor, taking into account type of disease, urgency of transplantation, donor characteristics and center experience. This review will analyze the current results of CBT for pediatric patients with malignant diseases and the advantages and limitations of using this stem cell source.
Introduction
Umbilical cord blood transplantation (CBT) has extended the availability of allogeneic hematopoietic SCT (HSCT) to patients who would otherwise not be eligible for this curative approach. As the first successful CBT from an HLA-identical sibling in a child with severe Fanconi's anemia reported by Gluckman et al. 1 in 1989, the number of CBT from related and unrelated donors has increased dramatically, and we estimate that more than 20 000 patients have undergone CBT from unrelated CBT donors (UCBT) to date for a variety of genetic, hematological, immunological, metabolic and oncological disorders. Progress in the field of umbilical CBT parallels the huge interest in establishing and developing cord blood banks worldwide. Today, more than 450 000 cord blood grafts are available in more than 50 cord blood banks. These banks have an important role in the process of CBT.
To develop research in different biological aspects of cord blood cells and evaluate cord blood transplants, the European Blood and Marrow Transplantation Group (EBMT) with the support of the European Union organized the Eurocord Group in 1995. One of the most important achievements of the Eurocord Group was the establishment of the Eurocord registry. It works in close collaboration with EBMT and Netcord banks, collecting and validating clinical data of patients transplanted with cord blood units, 3080 children (o18 years) have been transplanted with related (n ¼ 477) or UCBT (n ¼ 2559) for all diseases from 1988-2008. In the related CBT setting, 42% of children were transplanted for malignant diseases, whereas in the unrelated transplant setting, almost 70% had malignant diseases being acute leukemia the most frequent indication. Table 1 shows the number of CBT according to related or unrelated donor for malignant disorders and type of disease, reported to Eurocord Registry.
Risk factor analysis after related and unrelated CBT has been performed and compared to other HSCT donors. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Moreover, disease-specific analysis after unrelated CBT for AML, 13 ALL and myelodysplastic syndrome (MDS) have been carried out by the Eurocord Group.
Umbilical CBT from related donors
Related CBT (RCBT) has been carried out almost exclusively in children [2] [3] [4] [5] and studies reporting outcomes after CBT in children with malignant diseases is scarce in the literature. 4 Smaller numbers of RCBT for malignant disorders can be explained by the fact that if the pregnancy is planned, the time to transplant may be longer. /kg and at infusion was 4 Â 10 7 /kg. Most of the cord blood units were banked at the local institution where transplantation took place.
Median days of neutrophil and plt recovery were 23 (8-49) and 38 (12-165) days, respectively. Estimate probability of neutrophil recovery at day 60 was 89±3% and 180-day plt recovery was 81%. In a multivariate analysis for neutrophil recovery, HLA match was associated with increased probability of recovery (93% vs 72%, adjusted P ¼ 0.004). There was a trend of better recovery for patients receiving a higher cell dose (90% vs 85%, adjusted P ¼ 0.06). Acute GVHD (II-IV) was observed in 24 patients (II ¼ 23, III ¼ 5 and IV ¼ 2). HLA compatibility and higher cell dose were associated with decreased incidence of acute GVHD. In fact children receiving an HLA incompatible graft had an incidence of 46% compared with 17% of the remainders (Po0.001). Chronic GVHD was observed in 12% of patients at risk. At 5-years relapse incidence was 44% for patients transplanted in early phase of the disease, 54% in intermediate and 65% for those in advanced phase (P ¼ 0.04). TRM at 5 years was 21% and disease-free survival (DFS) was 40%. In a multivariate analysis for DFS, HLA compatibility (Po0.001), female gender (P ¼ 0.03), younger children (o5 years) (P ¼ 0.05) and children transplanted in remission (P ¼ 0.02) were factors associated with increased rates of DFS. In fact, 5-year DFS of children transplanted with an HLA compatible donor was 46% compared with 13% in those transplanted with an incompatible relative. In summary banking of a related HLA-identical unit should be encouraged when possible.
14 In this setting, HLA compatibility has an important role for outcomes after RCBT.
HLA-identical CBT compared with HLA-identical BMT in children A joint study by the Eurocord and International Bone Marrow Transplant Registry 8 has compared the outcomes of 113 children who received UCB from HLA-identical siblings with those of 2052 children who underwent HLAidentical sibling BMT. Of 61 children transplanted for malignancy, 47 had acute leukemia or CML. In all, 21% of these patients had early (first remission or first chronic phase) leukemia, 60% had intermediate (second or subsequent remission or accelerated phase) leukemia and 19% had advanced (not in remission or blast phase) leukemia. Median interval between diagnosis and transplantation was 25 months. Median follow-up was 27 months (range, 3-85 months). UCBT recipients had slower recovery of neutrophils and plts, and a lower risk of acute and chronic GVHD. Among patients receiving transplants for malignancy, 3-year survival was 46% for 61 patients receiving cord blood and 55% for 1263 receiving BM (P ¼ 0.69). These findings suggest that, in children in the HLAidentical sibling setting, UCBT is as useful as BMT. Based on these results, we recommend collecting and freezing cord blood units in families where a sibling child is suffering from a genetic or hematological disease. In order to have high quality familiar cord blood units, sibling cord blood bank programs should be established. 14 
Unrelated umbilical CBT from unrelated donor
Multicenter, 4,9,13 single institution 7, 10, 11 and consortium 15 studies have shown that unrelated donor UCBT in children is able to reconstitute hematopoiesis and achieve sustained engraftment in most cases is associated with a low incidence of GVHD; and does not result in a higher relapse risk. 9, 12 Recently, results of the first prospective phase 2 multicenter trial on UCBT (COBLT) for children with hematological malignancies have been published. 15 Cumulative incidence of neutrophil recovery, acute GVHD, chronic GVHD and relapse were 80, 19.5, 20.8 and 19.9% respectively. The 2-year overall survival was 49.5%. Risk factor analysis for outcomes showed the association of outcomes with cell dose, HLA disparities, ABO compatibility, patients CMV positivity, disease and disease status at transplantation. This prospective trial reinforced the use of cord blood cells in children with malignant diseases.
Results and risk factor analysis for outcomes after unrelated UCBT in children with ALL, AML 13 and MDS have been carried out by the Eurocord Group. In all those studies, status of the disease at transplant is the most important factor associated with final outcomes. Also cell dose, HLA disparity, period of transplantation and center experience are important factors that have to be taken into consideration in order to improve UCBT outcomes. Pediatric CB transplant for malignant diseases V Rocha et al
UCBT for children with ALL
Indications for allogeneic HSCT for childhood ALL has evolved over time because of improvements in treatment outcome with chemotherapeutic regimens and better understanding of risk factors, including novel ways to detect minimal residual leukemia and the intensity of therapy tailored to the risk status of a given patient. Transplantation is recommended for only a minority of patients in first CR and for the majority of those who experience relapse. Eligibility criteria for HSCT vary according to different chemotherapy protocols; most current protocols identify about 10% of all childhood ALL population presenting with dismal prognostic factors for HSCT. The role of HSCT is also influenced by changes in the technique of transplantation, mostly the increased availability of unrelated donors worldwide, the higher resolution of HLA typing, allowing better donor-recipient matching, and therefore improved results and the encouraging results of alternative donors, such as HLA matched unrelated, umbilical cord blood or fully haploidentical HSCT. 16 ALL represents the most common indication of UCBT among malignant diseases in children (Table 1) . Despite this, few reports of risk factor analysis after UCBT for childhood ALL have been carried out. We have analyzed a total of 361 children with ALL receiving an UCBT, from 1994-2005, in 24 countries, mostly in Europe (Eurocord, unpublished data). In all, 87 children with unfavourable cytogenetics were transplanted in first CR (89% had t(9;22) or t(4;11)); 152 children were transplanted in second CR; and 122 in more advanced disease. Median age was 6.5 years, median cell dose infused was 4.1 Â 10 7 /kg and the median follow-time was 22 months (3-96). The graft was HLA disparate in 80% of cases, with one or two incompatibilities (HLA-A and B low resolution typing or HLA-DRB1 by high resolution typing). Overall, 3 year leukemia-free survival (LFS) was 33±7% for patients in CR1; .35 ± 4% for patients in CR2; and 21 ± 4% for patients transplanted with advanced disease. On multivariate analysis, only CR1 and CR2 were associated with superior LFS (Po0.0001). In the group of children transplanted in CR2 (n ¼ 151) the main risk factor associated with improved 2 years LFS on multivariate analysis was a previous relapse before UCBT, either on or off therapy (P ¼ 0.02). In fact, 3 year LFS was 26% for patients relapsing while still receiving therapy compared with 45% for those relapsing off therapy (Figure 1 ). Other patient-specific factors, diseases and graft characteristics, (such as age, gender, CMV serology, cytogenetics, conditioning regimen, cell dose, HLA, and so on) were not associated with the outcome on multivariate analysis for patients transplanted in CR2 (Eurocord; unpublished data) /kg and the median follow-up was 31 months. Cumulative incidence (CI) of neutrophil recovery at day 60 was 78 ± 4%, 100-day acute GVHD was 35 ± 5% and 100-day TRM was 20 ± 4%. In multivariable analysis, a collected NC dose higher than 5.2 Â 10 7 /kg was associated with a lower 100-day TRM. The 2-year cumulative incidence of chronic GVHD was 15 ± 5%. The 2-year cumulative incidence of relapse was 29 ± 5% and was associated, in multivariable analysis, with disease status. Overall, the 2-year LFS were 42 ± 5%. It was 59 ± 11 % in CR1, 50 ± 8% in CR2, none among 5 in CR X3 and 21±9% for children not in CR. It is interesting to note that children with a poor karyotype had similar LFS compared with other patients (44 ± 11 vs 40 ± 8%). In children transplanted in CR2, LFS was not influenced by the length of CR1 (53±11% for CR1o9.5 months compared with 50 ± 12% for later relapses).
Recently, we have carried out a survey on 290 children given an unrelated single unit CBT. UCBTs were carried out from 1994-2008. Eighty-four children (29%) were transplanted in CR1, 46% in CR2 and 25% in a more advanced phase of the disease. Median age was 6 years (0.3-18) and median follow-up 23 months (3-149). Twoyears LFS was 65% for those transplanted in CR1, 43% for CR2 and 22% for those who were in the advanced phase of the disease (Figure 2 ).
UCBT for children with MDS
Myelodysplastic syndromes are rare diseases in children, and HSCT remains the only treatment with curative potential. 17, 18 Although outcomes and risk factors after with results comparable to those obtained after unrelated BMT, [9] [10] [11] [12] there are few reports investigating the outcome of children with MDS given an unrelated donor transplantation and evaluating potential risk factors. Most of these reports are limited to small and heterogeneous series, [17] [18] [19] [20] including JMML and/or secondary AML and some adults. [17] [18] [19] [20] In
. Median age at transplantation was 7 years, while the median follow-up was 3 years. UCB units were HLA matched (n ¼ 4), mismatched at 1-locus (n ¼ 34), 2-loci (n ¼ 26) and 3-loci (n ¼ 5) with the recipients. The day-60 probability of neutrophil recovery was 76%; a cell dose 46 Â 10 7 /kg, transplantation of HLA matched or 1-locus mismatched UCB and irradiation-containing conditioning regimen favored faster engraftment. The overall 3-year probability of disease-free survival was 39%; it was 66% when transplantation was carried out within 6 months from diagnosis as compared with 20% for patients grafted after a longer interval from diagnosis. Transplantation-related mortality was lower in children given the allograft after 2001. These data indicate that transplantation with UCB is an acceptable alternative in the absence of a matched donor and early referral for transplantation may be a key determinant for a successful outcome.
Retrospective studies comparing CBT with other alternative donors allogeneic HSCT
The use of alternative hematopoietic stem cell donors has witnessed important progress, mainly because of the following reasons: (i) better HLA matching at the allelic level between donor and recipient in unrelated HSCT translating into better patient outcome; (ii) better donor choice and patient selection in unrelated, often HLAmismatched, CBT; and (iii) new strategies of adoptive cell therapy, aimed at improving the results of T-cell depleted haploidentical HSCT from a relative. 16, 21, 22 At present, it is possible to find an HSC donor for virtually almost all children with an indication to receive allogeneic HSCT and lacking an HLA-identical sibling and each of the three options of HSCT from alternative donors has advantages and limitations (Table 2) . 16 
Comparison of outcomes after umbilical CBT and adult unrelated unrelated HSCT donor in children with leukemia
Comparison of the results of UCBT and unrelated BMT (UBMT) in children is of paramount relevance, because for many patients the search process will identify both unrelated Table 2 Advantages and limitations of unrelated donor BMT, UCBT and haploidentical HSCT from a relative: main criteria to be considered for choosing an alternative donor for patients without an HLA-identical sibling Pediatric CB transplant for malignant diseases V Rocha et al CB units and unrelated BM donors. Three published studies, two single center studies and a Eurocord registry series, have reported retrospective analyses comparing outcomes after UCBT and UBMT in children. 9, 10, 11 Briefly, in these three studies, recipients of UCBT were transplanted sooner compared with children given UBMT; neutrophil and plt recoveries were delayed, acute GVHD was less and overall survival was insignificantly different after UCBT compared with UBMT. The Eurocord Group has reported higher early TRM, probably due to infections related to delayed engraftment. It is important to note that all patients in the Eurocord series were transplanted before 1998, when UCBT was still considered to be a last option for leukemia treatment.
A meta-analysis combining these comparative studies was published. 23 A total of 161 children undergoing UCBT (mostly one or two Ag-mismatched), and 316 children undergoing UBMT (almost entirely fully matched with the recipient), were analyzed. Pooled comparisons of studies of UCBT and UBMT in children found that the incidence of chronic GVHD was lower with UCBT, but the incidence of grade III-IV acute GVHD did not differ. There was no difference in the 2-year OS between children given an unrelated UCBT or UBMT.
All these previous comparative studies have analyzed HLA matched BMT using the definition of low resolution HLA-A and -B typing, and high-resolution HLA-DRB1 typing. In a more recent published analysis, Eapen et al, /kg) and 2-loci mismatched cord blood (any cell dose) (P ¼ 0.005, Po0.001, respectively). Conversely, relapse rates were lower in recipients of cord blood mismatched at 1 or 2-loci (P ¼ 0.037, P ¼ 0.003, respectively). As previously observed, the probability of neutrophil recovery (4500/ml) at day 42 depended on graft type, HLA-match and cell dose (98% with BM; 85% with matched cord blood; 79% with 1 or 2-loci mismatched cord blood/high cell dose; 64% with 1 or 2-loci mismatched cord blood/low cell dose). Compared with allele-matched BM, risks of grade 2-4 and grade 3-4 acute GVHD were lower after matched cord blood (relative risk 0.45, P ¼ 0.035, relative risk 0.51, P ¼ 0.035, respectively) and similar after mismatched cord blood. Risk of chronic GVHD was lower after matched or mismatched CBT (relative risk 0.66, P ¼ 0.036).
These data strongly suggest that UCB is an acceptable alternative to matched unrelated BM in children, and support starting a simultaneous search for BM and UCB unrelated donors. The final selection of unrelated donor BM vs UCB should be based on the urgency of the transplant, and characteristics of the BM and UCB unrelated donor such as cell dose and HLA compatibility. For those children requiring an urgent transplantation, generally in less than 3 months, UCB seems advantageous. Moreover, cord blood banks should increase their inventories, with the aim of finding more closely matched cord blood grafts. 24 Comparison of outcomes after umbilical CBT in children with full haplotype donor HSCT
The Eurocord Group in collaboration with the Acute Leukemia Working Party and the Pediatric Diseases Working Party of the EBMT have compared the outcome of patients given either UCBT or haplo-HSCT, by carrying out a retrospective comparison of pediatric patients (16 years or younger) with high-risk ALL. 25 Children had received either haplo-HSCT (n ¼ 118) or UCBT (n ¼ 341) in EBMT-Eurocord centers between 1998 and 2004. Haplo-HSCT recipients tended to be older, had CMV positive serology and t(9;22) more frequently. The median followup was 56 months and 24 months for haplo-HSCT and UCBT patients, respectively. Failure of engraftment was significantly higher after UCBT than after haplo-HSCT (23 vs 11%, P ¼ 0.007). In multivariate analysis, adjusted for differences between the groups and prognostic factors, relapse incidence was higher in haplo-HSCT recipients compared with UCBT (relative risk ¼ 1.7, P ¼ 0.01), but TRM and DFS were insignificantly different. In conclusion, in pediatric patients with ALL, UCBT is associated with inferior rate of engraftment, higher incidence of grade II-IV acute GVHD and lower incidence of relapse compared with haplo-HSCT; however, there was no difference in terms of TRM and DFS. Therefore, in the absence of an HLA-identical donor, both strategies are suitable options to treat a child with high risk ALL.
Improving outcomes after UCBT in children
Almost all pediatric series concerning UCBT from unrelated donors have demonstrated the profound impact of cell dose, measured as total NCs, colony-forming cells and CD34 þ cells, on engraftment, adverse transplant-related events and survival. 2, 6, 7, 13 Although the prognostic importance of HLA disparity was not clearly recognized in earlier series, it has become apparent in recent updates. 6, 12, 26 It has been suggested that cell dose and number of HLA mismatches interact mutually on engraftment and on other outcomes. Thus, a higher cell dose in the graft could partially overcome the negative impact of HLA for each level of HLA disparity, but this hypothesis has not been yet been fully demonstrated. However, based on previous data 6, 7 and Eurocord data, 2, 26 we recommend cord blood grafts with no more than two HLA disparities and with more than 2.5 or 3 Â 10 7 /kg NCs at cryopreservation. Other factors such as diagnosis and status of the disease at transplant have an important role in rate of engraftment. This is because of the fact that most patients have a full marrow and have not received chemotherapy or immunosuppression before conditioning. Recently, in the light of the observation that requirements regarding cell dose and HLA matching may differ in malignant diseases, we attempted to construct an algorithm to guide clinicians in choosing the 'best' cord blood unit, taking into account the impact of diagnosis, cell dose and HLA incompatibilities, in patients receiving a single UCBT. If the cell dose with a single unit is not achieved, a double CBT should be possible. With this objective, two different cohorts of patients who had received a single UCBT between 1994 and 2005 were analyzed: 925 patients had a malignant disease (Eurocord; unpublished data). Donor-recipient histocompatibility was determined by serology or Ag typing for HLA-A and HLA-B and by DNA typing for HLA-DRB1. The median age was 11 years (20% were adults 418 years). Diagnoses included AML in 25%, ALL in 44%, chronic leukemia in 9% and MDS in 10% of cases. Only 9% were classified as having class I Ag and class II alleles identical to their donor; 42% had one HLA difference, 40% had two HLA differences and the remainder had three or four HLA differences. For patients who had one HLA mismatch, 67% had class I difference and 33% had class II difference. For patients with two HLA differences, 38% had two class I differences, 7% had two class II differences, and 55% had a difference of one class I and one class II. The median number of NCs infused was 3.1 Â 10 7 NC/kg (range 2-5 Â 10 7 NC/kg). At day 100, the cumulative incidence of neutrophil recovery (the first day the neutrophil count reached 4500 neutrophils/ml) was 77% and the cumulative incidence of plt recovery (the first day plt count reached 420 000 plts/ml) was 54.7%. This related to the number of cells infused (Po0.0001). HLA was a second factor that affected neutrophil engraftment, with a difference between 0-1 (81%), 2 (75%) and 3-4 (63%) HLA incompatibilities (P ¼ 0.037).
We found that cell dose was the most important factor influencing neutrophil and plt recovery and early TRM; a minimum cell dose of 3 Â 10 7 NC/kg at collection, and of 2 Â 10 7 NC/kg at infusion needed to be targeted. We also showed that the number of HLA mismatches increased the risk of delayed engraftment and led to a higher incidence of TRM and chronic GVHD; however, it decreased the risk of relapse, resulting in an overall lack of influence of HLA mismatching on OS and DFS. Type of HLA mismatch did not influence the final outcome, but matching for HLA-DRB1 appeared better for patients receiving a graft that had two HLA incompatibilities. As stated earlier, increasing cell dose abrogated the effect of HLA mismatching, but not for grafts with three or four HLA incompatibilities.
Survival rates after UCBT for children with malignant disorders have improved since the very beginning of the use of cord blood cells (Figure 3 ). This improvement is associated with factors related to patients, disease, donor choice and center experience. In fact, with the increased pool of cord blood units available for transplantation it becomes easier to select units that contained high number of cells and low number of HLA disparities. Moreover over the time, clinicians indicate transplantation in the early phase of diseases compared with the early period of UCBT when only patients in advanced phase of the disease were transplanted with cord blood cells (Figure 4 ).
Conclusion
Related cord blood transplantation and UCBT are established options to treat children who have high-risk leukemia or other malignant disease, or have relapsed after standard therapy and those who do not have an immediate match related or unrelated adult donors. Such children should be immediately referred and evaluated for unrelated CBT before their disease status worsens, otherwise their chances of successful outcome with transplantation therapy would decrease. The choice of the donor will depend on various factors related to urgency of transplantation with patient-, disease-and transplant-related factors and center experience. 
